Parkinson’s disease (PD) is a chronic, progressive movement disorder that affects the lives of between 500,000 and 1 million Americans. People with PD experience changes in movement, including slowness and rigidity, and may also notice changes including sleep, fatigue, mood, attention and memory, bowel and bladder function, all of which have considerable impact on quality of life. Currently available drugs and surgical treatments improve movement, but are less effective in treating other symptoms or slowing the progression of PD. Significant research is focused on understanding the causes of PD and the discovery of improved treatments.
For general information, please see the NINDS Parkinson's Disease Information Page.
For further information on NINDS programs for Parkinson's Disease research, please contact Beth-Anne.Sieber@nih.gov.
At the National Institutes of Health (NIH), the NINDS is the primary institute supporting PD research:
- In fiscal year 2021, the NINDS funded approximately $129 million out of a total of $254 million in NIH-supported PD research.
- The NINDS supports basic, translational and clinical research programs through investigator-initiated research and dedicated programs, including the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research and the Parkinson's Disease Biomarkers Program (PDBP).
- PD research resources supported by the NINDS include the Biospecimen Exchange for Neurological Disorders (BioSEND) repository , the Data Management Resource for clinical data and the NINDS Human Cell and Data Repository.
- The NINDS participates in the Accelerating Medicine Partnership for Parkinson's Disease (AMP PD), a public-private collaboration focused on biomarker discovery to advance the development of PD therapies.
- As part of our mission to decrease the burden of neurological disease, and building upon a strong foundation of research discovery, the NINDS is committed to the rapid translation of basic research findings into clinical practice for PD.
Estimates of Funding for Various Research, Condition, and Disease Categories
| Research/Disease Areas* | FY 2020 |
FY 2021 |
FY 2022 |
FY 2023 (est) |
|---|---|---|---|---|
| Parkinson's Disease | $242 | $254 | $259 | $270 |
Proceedings & Outcomes
NINDS Parkinson's Disease 2014 Conference: Advancing Research, Improving Lives: To inform ongoing and future efforts in PD research, the NINDS organized the “PD2014” conference (January 6-7, 2014). At this public meeting, participants assessed significant challenges and identified the highest research priorities for advancing basic, translational and clinical research on PD. Identified research priorities and access to the archived meeting webcast are available.
Resources and Tools
Contacts
Beth-Anne Sieber, Ph.D. | Program Director, Movement Disorders and Neurodegeneration
Beth-Anne.Sieber@nih.gov
Debra Babcock, M.D., Ph.D. | Program Director, Systems and Cognitive Neuroscience
Debra.Babcock@nih.gov
Sophie (Hyun Joo) Cho, M.D. | Program Director, Division of Clinical Research
Hyunjoo.Cho@nih.gov
Christine Swanson-Fischer, Ph.D. | Program Director, Movement Disorders and Neurodegeneration
Christine.Swanson-Fischer@nih.gov
Rebecca Price, Ph.D. | Program Manager, Movement Disorders and Neurodegeneration
Rebecca.Price@nih.gov
Luis Sullivan, Ph.D. | Health Program Specialist, Movement Disorders and Neurodegeneration
Luis.Sullivan@nih.gov
Hsiao Yu (Christina) Fang, Ph.D. | Health Program Specialist, Movement Disorders and Neurodegeneration
Christina.Fang@nih.gov
Funding Opportunities
Parkinson's Disease Funding Opportunities
Alzheimer's Disease and Related Dementias Funding Opportunities
To receive regular updates on funding announcements and other opportunities, please join the NINDS PD Research ListServ
News & Events
NIH researchers identify large genetic changes that contribute to dementia risk
Neurology Podcast: NINDS Support for PD Research, with Dr. Sophie Cho
Parkinson’s Awareness Month: NINDS Contributions to Research and Potential Treatments
Artificial intelligence model can detect Parkinson’s from breathing patterns
Genetic study of Lewy body dementia supports ties to Alzheimer’s and Parkinson’s diseases
Related Topics
NINDS Biospecimen Exchange for Neurological Disorders (BioSEND)
BioSEND houses biospecimens collected through NINDS-supported studies including phase 2 and 3 clinical trials along with an array of studies focused on biomarkers of disease susceptibility, onset and progression. The primary goal of the BioSEND repository is standardize biospeciment collection and distribution to facilitate research on PD and neurological disorders. BioSEND currently banks a variety of biospecimens, including DNA, plasma, serum, RNA, CSF, urine, and saliva.NINDS Human Cell and Data Repository (NHCDR)
NHCDR provides well-characterized cell sources to both academic and industry investigators to advance the study of neurological disorders including PD. Cell sources currently include fibroblasts and/or induced pluripotent stem cells. NHCDR also provides new tools for analytics, searching and ordering for all components of the repository.NINDS Data Management Resource (DMR)
The NINDS Data Management Resource (DMR) advances Parkinson's research through the support of electronic data capture, clinical site management, data quality assessment and data access. This resource provides researchers with tools that allow for the collection and quality assurance of data in a standardized format. In addition, the DMR coordinates entry of de-identified data into a common database, enabling the query and distribution of aggregate, harmonized clinical data.NINDS Common Data Elements (CDEs)
Common Data Elements (CDEs) are standards that enable clinical investigators to systematically collect, analyze and share harmonized data across the research community. The NINDS strongly encourages researchers who receive funding from the Institute to ensure their data collection is compatible with these CDEs.NIH NeuroBioBank
The NIH-funded NeuroBioBank (NBB) is a national resource and repository for human post-mortem brain tissue and related biospecimens that are crucial to understand both healthy brain function and nervous system dysfunction in nervous system disorders, including PD. The goals of the NBB are to 1) increase the availability of human disease and control brains by increasing public awareness of the value of tissue donation for understanding brain disorders; 2) facilitate the distribution of high quality, well characterized human post-mortem brain tissue for the research community; and 3) to serve as a centralized research resource of best practices and protocols used by six networked sites in the acquisition, preparation, and distribution of tissue.
- Public: Learn about the crucial need for brain donation and how the gift of brain donation can advance knowledge of neurological disorders, including PD. The NIH NeuroBioBank has partnered with The Brain Donor Project to help potential donors register for brain donation.
- Researchers: Browse the inventory of available samples and learn how to request tissue from NBB.
NINDS Contributions to Approved Therapies: DBS for PD
An overview of the successful development of DBS as a therapy for PD, including contributions from basic neuroscience research and clinical studies supported by the NINDS and NIH.Related Disorder Information